Platform for post-authorization studies registered as EU trade mark

The European Union Intellectual Property Office (EUIPO) has approved the registration of ‘EU PAS Register’ as a European Union trade mark (EUTM), thus granting exclusive rights in all current and future EU member states, and can be renewed every 10 years.

Launched in November 2010, the EU PAS Register is a unique source of information on the safety and effectiveness of authorized medicines. It is an openly accessible platform with information on observational  1 post-authorization research in medicines already marketed in Europe and includes study protocols, study results, related publications and other relevant information.

The information in the EU PAS Register helps to reduce publication bias through increased transparency of medicines research, improves the quality of post-authorization studies by facilitating peer-review of protocols and results, promotes collaboration among stakeholders, and ensures compliance with EU pharmacovigilance legislation requirements.